France issues stringent pricing, regulatory guidelines

04/30/2013 | Clinica

France is now requiring that its health care authority review real-world data about pricing decisions for reimbursed drugs and devices, and that companies conduct stringent post-reimbursement studies to determine price-control levels. At present, the government uses cost-benefits studies by the country's independent health authority to set prices for reimbursed products. The government is also seeking to cut prices for generics by even greater amounts than previously through a "reference price" mechanism.

View Full Article in:

Clinica

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC